Switching from Wegovy or Zepbound to Foundayo: What ATTAIN-MAINTAIN Shows

For the past year, the question patients on injectable GLP-1s have been asking their prescribers is some version of: can I switch to a pill yet? With Foundayo (orforglipron) FDA-approved on April 1, 2026 (FDA press release), the answer is now yes. The follow-up question, which matters more, is whether you should. Two newly published Nature Medicine papers, ATTAIN-MAINTAIN and ATTAIN-2, finally give that question a real answer. The honest verdict: switching from Wegovy or Ozempic to Foundayo preserves most of your weight loss, switching from Zepbound or Mounjaro to Foundayo costs you meaningfully more, and both moves are clinically reasonable depending on tolerability, cost, and whether you want to stop injecting.

TL;DR

• Wegovy/Ozempic → Foundayo: average regain of about 0.9 kg (~2 lbs) over a year. Small. A reasonable swap if you want to stop injecting or cut cost.
• Zepbound/Mounjaro → Foundayo: average regain of about 5.0 kg (~11 lbs) over a year. Meaningfully larger. The data argues against this switch if you're responding well to tirzepatide.
• Cardiometabolic benefits (blood pressure, lipids, glucose markers) were preserved in both cohorts after the switch.
• Cost: switching to Foundayo can save $50–$200/month vs brand-name injectable telehealth pricing, especially through LillyDirect for patients with an existing prescription.
• Foundayo is FDA-approved as a finished product. That sets it apart from compounded oral semaglutide formulations, which are not FDA-approved as finished products.

What ATTAIN-MAINTAIN Actually Tested

ATTAIN-MAINTAIN is a phase 3b, double-blind, placebo-controlled trial published in Nature Medicine in May 2026 (Nature Medicine, 2026). The design is the first of its kind for the oral GLP-1 question: patients already on an injectable GLP-1 were randomized to either Foundayo or placebo for the maintenance phase, with weight regain and cardiometabolic outcomes tracked over the year.

The trial enrolled two cohorts, both drawn from populations who had completed earlier injectable GLP-1 protocols:

• Cohort 1 (N=205): previously treated with tirzepatide (the molecule in Zepbound and Mounjaro) during the SURMOUNT-5 study, then randomized to oral orforglipron or placebo.
• Cohort 2 (N=171): previously treated with semaglutide (the molecule in Wegovy and Ozempic), then randomized to oral orforglipron or placebo.

The endpoint that matters most for prospective switchers: how much of your prior weight loss does the pill preserve compared to stopping treatment altogether (placebo)?

What the Trial Found, by Cohort

The results split cleanly along which injection you were on.

Wegovy/Ozempic (semaglutide) → Foundayo: patients in this cohort regained on average about 0.9 kg (roughly 2 lbs) over the year (Nature Medicine, ATTAIN-MAINTAIN, 2026). For context, typical injectable semaglutide weight loss is around 15% of body weight, so a 2-pound regain represents a small fraction of total loss. Functionally, Foundayo held the line.

Zepbound/Mounjaro (tirzepatide) → Foundayo: patients in this cohort regained on average about 5.0 kg (roughly 11 lbs) over the year (Nature Medicine, ATTAIN-MAINTAIN, 2026). That's a meaningfully larger share of the typical Zepbound weight loss, which is around 20% of body weight on the highest dose. The pill maintained most of the benefit, but not all of it.

Cardiometabolic markers in both cohorts: improvements in blood pressure, lipid profile, and glucose markers achieved on the injectable were preserved through the year on Foundayo (Nature Medicine, ATTAIN-MAINTAIN, 2026). The benefits weren't just about weight.

Side effects after the switch were consistent with the broader GLP-1 class profile (nausea, constipation, diarrhea, mostly during dose escalation), with no new safety signals reported.

Why the Asymmetry: Wegovy vs Zepbound Switching

The gap between cohorts has a clean mechanistic explanation, and it's the single most important thing to understand before deciding.

Tirzepatide is a dual GLP-1 and GIP receptor agonist. It binds two distinct gut hormone receptors. Semaglutide is GLP-1 only. Orforglipron is GLP-1 only. So when a Wegovy patient switches to Foundayo, they're swapping a peptide GLP-1 for a small-molecule GLP-1; same fundamental class, just a different molecule and delivery format. When a Zepbound patient switches to Foundayo, they're losing GIP receptor activity entirely. A single-receptor pill cannot fully replicate a dual-receptor injection.

The honest implication: if you're on tirzepatide and the medication is working, the published evidence argues for staying on it. For context on why tirzepatide and semaglutide produce different weight loss in head-to-head data, see our tirzepatide vs semaglutide comparison.

The ATTAIN-2 Angle: What If You Have Type 2 Diabetes?

ATTAIN-MAINTAIN isn't the only Nature Medicine paper Lilly published this month. ATTAIN-2 is a 72-week phase 3 trial of Foundayo in adults with obesity or overweight plus type 2 diabetes, a population the original ATTAIN-1 trial didn't cover (Nature Medicine, ATTAIN-2, 2026; trial registration NCT05872620).

At the highest dose, ATTAIN-2 reported mean weight loss of about 10.5% (roughly 22.9 lbs), A1C reduction of 1.3% to 1.8% from a baseline of 8.1%, and 75% of participants achieving an A1C of 6.5% or lower, the threshold often used to define T2D remission (Nature Medicine, ATTAIN-2, 2026).

The practical takeaway for switchers with T2D: Foundayo is a genuine type 2 diabetes plus obesity option, not just an obesity-only pill. If you're currently on an injectable for both indications, the published efficacy supports Foundayo as a reasonable consolidation move. Talk to your endocrinologist about whether the A1C trade-off versus your current injection makes sense for your trajectory.

Cost: Is Switching to Foundayo Cheaper?

For most cash-pay patients, yes. The size of the savings depends on which path you use.

Prices reflect what providers advertised as of May 2026 and may change.

Path	Foundayo monthly cost	Notes
LillyDirect (manufacturer-direct)	$149/mo at 0.8mg, $199/mo at 2.5mg, $299/mo at 5.5–9mg, $349/mo at 14.5–17.2mg (or $299/mo with 45-day refill via Self-Pay Savings Program)	Cheapest verified Foundayo path overall. Requires existing prescription. No clinical care included.
Found	$149/mo medication + $99–$149/mo CORE membership = $248–$298/mo total	Cheapest verified telehealth path. CORE membership tier scales by plan length.
Shed	$149/mo medication + $125/mo Shed Membership = $274/mo total	Widest format catalog if you want options.
Hers	$149/mo medication + $149/mo membership = $298/mo total ($39 first month)	Women-focused. Novo Nordisk partner with full brand catalog.
Hims	$149/mo medication + $149/mo membership = $298/mo total ($39 first month)	Full brand-name catalog. Novo Nordisk partner.
Ro	$149/mo first month, then $199–$299/mo + $149/mo membership	Pricing escalates after first month.

Compare that to brand-name injectable GLP-1s through telehealth, which typically run $274–$498/mo all-in depending on provider, dose, and membership tier. For most cash-pay patients on Wegovy or Zepbound through a telehealth platform, switching to Foundayo via the same platform or via LillyDirect saves between $50 and $200 per month.

For a live filterable view of provider pricing, see our GLP-1 pricing tool. For insurance-route detail, see our GLP-1 insurance coverage guide.

Should You Switch? A Practical Framework

The data and the cost numbers point in different directions for different patients. Here's the honest version of the decision tree.

Consider switching if:

• You hate injections, even after a year of them. Some patients never adjust to weekly self-injection, and the daily pill is a meaningful quality-of-life upgrade.
• You're on injectable semaglutide (Wegovy or Ozempic) and tolerating it well. ATTAIN-MAINTAIN shows minimal regain in this cohort.
• Cost matters more than maximum weight effect. The savings are real for cash-pay patients.
• You have type 2 diabetes and want a single oral option. ATTAIN-2 supports Foundayo for this population.
• You travel frequently or live somewhere refrigeration is a hassle. Pills are room-temperature stable; pens require refrigeration before first use.

Hold off if:

• You're responding really well to Zepbound or Mounjaro. The 11-pound average regain in ATTAIN-MAINTAIN's tirzepatide cohort is the clearest negative signal in the trial.
• You've recently started a GLP-1. Let the dose stabilize for at least 6 to 12 months before considering a switch; you don't yet know what your sustained response looks like.
• Your insurance covers your current injection at a low copay. The cost case for switching disappears when insurance is doing the work.
• You have a complex medication regimen and want the simplest possible routine. Foundayo can be taken any time of day with or without food, but the dose escalation period still requires attention.

Dose Mapping: Where to Start Foundayo

Foundayo's titration schedule has six dose tiers: 0.8mg starter, then 2.5mg, 5.5mg, 9mg, 14.5mg, and 17.2mg (Eli Lilly press release, April 2026). Lilly has not published an official equivalency table between injectable GLP-1 doses and Foundayo doses, and in practice there isn't a clean one.

Most patients will follow the standard Foundayo titration schedule regardless of their previous injectable dose, with the timeline adjusted by their prescriber based on tolerability history. If you tolerated your injectable well, your prescriber may move you up the dose ladder faster than a treatment-naive patient. If you struggled with side effects, the standard slow titration applies. Don't assume your current injectable maintenance dose maps to a specific Foundayo dose; that's a conversation with your prescriber, not a calculation.

Side Effects After the Switch

Here's what to expect realistically in the transition.

Even if you've been stable on an injectable for months with no significant GI symptoms, dose escalation on Foundayo can bring some nausea, constipation, or diarrhea back. The class profile is consistent across all GLP-1s (injectable or oral, peptide or non-peptide), and dose escalation is when the bowel adjusts. ATTAIN-MAINTAIN reported overall tolerability after the switch consistent with the broader GLP-1 class (Nature Medicine, ATTAIN-MAINTAIN, 2026).

The transition window is typically 4 to 8 weeks. Standard advice applies: titrate slowly under your prescriber's direction, hydrate aggressively, prioritize lean protein, eat smaller meals, and call your prescriber if symptoms become severe or persistent. For deeper detail, see our GLP-1 side effects guide.

Where to Switch: Provider Options

If you're paying cash and already have a prescription, the manufacturer-direct path is the cheapest medication-only option. If you need prescribing and ongoing care included, telehealth providers add a membership layer on top of the medication price.

LillyDirect is the price floor for Foundayo if you already have a prescription: $149/mo at 0.8mg starter, escalating by dose. There's no telehealth markup because there's no telehealth layer; you bring your own prescription and Lilly fulfills it. For patients who already have an established prescriber and don't want to repeat the intake process, this is the cheapest path. Hims and Ro also stock Foundayo at the same medication price ($149/mo) with similar membership structures.

The Bottom Line

The ATTAIN-MAINTAIN data turns "should I switch to Foundayo?" from a guess into a calculation. If you're on Wegovy or Ozempic and you'd rather take a pill, the average 2-pound regain is small enough that the switch is reasonable, especially if cost matters. If you're on Zepbound or Mounjaro and the medication is working, the average 11-pound regain is large enough that the data argues for staying put. If you have type 2 diabetes plus obesity and want one oral medication for both, ATTAIN-2 supports Foundayo as a real option.

Cost-wise, switching saves $50 to $200 per month for most cash-pay patients moving from brand-name injectable telehealth pricing to either LillyDirect direct or a telehealth platform stocking Foundayo. If you have insurance covering your current injection at a low copay, the cost case mostly disappears, and the decision comes down to format preference and tolerability.

Any switch is a conversation with a licensed healthcare provider who knows your history. If you want help figuring out which provider to use for the switch, our 10-question quiz takes about three minutes and produces a personalized ranking based on your dose, budget, and preferences.